Effect of oxytocin and flunixin meglumine on uterine response to insemination in mares.
The most probable reason for persistent postbreeding endometritis in mares is weak myometrial contractility. The influence of oxytocin (OT; an ecbolic agent) and flunixin meglumine (FLU; a prostaglandin inhibitor serving as a model for mares with decreased uterine contractility) on uterine response to artificial insemination (AI) was studied in mares with no history of reproductive failure. The mares were treated intravenously with 10 mL saline (Group C, n=10) or 0.01 IU/kg OT (Group OT, n=10) 2, 4, 8, and 25 h after AI. Group FLU (n=11) was treated with 1.1mg/kg FLU 2h after AI and with saline thereafter. The mares received the same treatments in the first and third cycles but were sampled either at 8 or 25 h. The amount of intrauterine fluid (IUF) and edema and the number of uterine contractions were recorded before AI and 10 min after the treatments using transrectal ultrasonography. At 8h after AI, the mares were treated with human chorionic gonadotropin, and, after 8-h or 25-h scans, a 500-mL uterine lavage and a biopsy were performed. Ovulation was confirmed at 48 h and pregnancy 14 to 17 d after AI. No manipulations were done during the second estrus. At 8h after AI, Group FLU had more polymorphonuclear leukocytes (PMNs) in the uterine lavage fluid than did Group OT (P<0.05), but uterine contractions did not differ significantly. At 25 h, the PMN concentrations were low in all groups. Group OT rarely showed IUF. The uterine biopsy specimens of Group FLU showed less inflammation of the stroma but more PMNs in the uterine lumen 8h after AI than that of the control group (P<0.05). The pregnancy rates did not differ between the groups (63% C, 53% OT, and 50% FLU). Oxytocin rapidly and effectively removed IUF and PMNs after AI and thereby shortened the duration of postbreeding inflammation.
Service of Research and Technological Development, Junta de Extremadura, Estate La Orden, Guadajira (Ba), Spain.
A M
AM
Risco
T
T
Reilas
L
L
Muilu
M
M
Kareskoski
T
T
Katila
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001826:Body Fluids / Q000737:chemistry / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000502:physiology; D003002:Clonixin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006736:Horses; D007315:Insemination, Artificial / Q000502:physiology* / Q000662:veterinary; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D010120:Oxytocics / Q000494:pharmacology; D010121:Oxytocin / Q000494:pharmacology*; D011247:Pregnancy; D018873:Pregnancy Rate; D014590:Uterine Contraction / Q000187:drug effects / Q000502:physiology; D014599:Uterus / Q000187:drug effects* / Q000276:immunology / Q000502:physiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010120:Oxytocics; D010121:Oxytocin; C014558:flunixin meglumine; D003002:Clonixin